Business Context and Reporting Period
This Form 6-K/A filing by GlaxoSmithKline plc covers the period ending February 2015. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility (PDMR), or connected persons, specifically regarding the vesting of conditional share awards.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial metric disclosed is the fair market value of an American Depositary Share (ADS) at the point of vesting on February 17, 2015, which was US$47.71.
Material Changes
The material event reported is the vesting of awards made in 2012 under the GlaxoSmithKline Share Value Plan (SVP). The restricted period for these awards, which commenced on August 22, 2012, has ended. Specifically, 2,300 Ordinary Shares vested for Mrs. K. Slaoui, a connected person of Executive Director Dr. M. Slaoui. No ADSs were vested for this individual.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, outlook, risk factors, or discussion of contingencies. It is strictly a compliance notification under Disclosure and Transparency Rule 3.1.4R(1)(c).
Key Facts for Investor Verification
- Transaction Type: Vesting of 2012 Share Value Plan awards.
- Beneficiary: Mrs. K. Slaoui (connected person of Executive Director Dr. M. Slaoui).
- Quantity Vested: 2,300 Ordinary Shares (0 ADSs).
- Vesting Date: February 17, 2015.
- Share Price at Vesting: US$47.71 per ADS.
- Reporting Date: February 18, 2015.